Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 11/20 | 0.90 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.90 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989312 | 0.95 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL18985115 | 0.86 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL17398232 | 0.78 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL6558703 | 0.78 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL433117 | 0.78 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL2045328 | 0.76 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL165812 | 0.76 | CHRNB4 (0.87) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL7698599 | 0.74 | CHRNB4 (0.59) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL13114824 | 0.74 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL9583820 | 0.74 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | claimed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | claimed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | disclosed |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| EP-1893613-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138604-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | CHRNB4 544/4885CHRNA3 241/4885CHRNA7 313/4885 |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | CHRNB4 544/4885CHRNA3 241/4885CHRNA7 313/4885 |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | CHRNB4 544/4885CHRNA3 241/4885CHRNA7 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.